As bleak as it sounds? Analysing trends in oncology clinical trial initiation in the UK from 2010 to 2022
Open Access
- 14 August 2024
- journal article
- Published by BMJ in BMJ Oncology
- Vol. 3 (1) , e000410
Abstract
Objectives: The UK’s withdrawal from the European Union (a political movement known as ‘Brexit’) incited concern both in the public and private sector about the future of drug development and the clinical trial landscape in the UK. This study evaluates trends in the initiation of phase III clinical trials that evaluated systemic anticancer treatments from 2010 to 2022 both in the UK and worldwide. Methods and analysis: Relevant clinical trials were identified through ClinicalTrials.gov. Initiation date in each country was defined as the date that a study’s record was updated to include a recruiting site in the country of interest. Concurrent clinical site counts were defined as the number of facilities that contemporaneously hosted trials. Temporal trends in trial initiation and site counts were evaluated. Results: Our analysis uncovered a worldwide increase in clinical trial initiation from 2013 to 2019. The UK experienced a decrease in clinical trial initiation immediately post-Brexit in 2020 but rebounded in 2021. The UK’s resurgence in clinical trials in 2021 was driven predominately by industry-funded trials. Other countries saw a similar increase in clinical trial initiation from 2020 to 2021. Conclusions: The UK’s trends in phase III oncology clinical trial initiation from 2010 to 2022 largely reflects global trends, suggesting that other factors (eg, COVID-19 pandemic) beyond Brexit, may have had a stronger influence on clinical trial initiation within the UK.Keywords
Funding Information
- National Cancer Institute (U24 CA248010, U24 CA265879)
This publication has 20 references indexed in Scilit:
- The future of cancer care in the UK—time for a radical and sustainable National Cancer PlanThe Lancet Oncology, 2023
- Horizon Europe turmoil changed the lives of these five scientistsNature, 2023
- UK oncology approvals in 2022: global regulatory collaboration and new regulatory pathways deliver new anti-cancer therapiesThe Lancet Oncology, 2023
- From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following BrexitThe Lancet Oncology, 2023
- Now is Our Opportunity to Revolutionise Cancer Clinical TrialsClinical Oncology, 2022
- The Impact of COVID‐19 on the Initiation of Clinical Trials in Europe and the United StatesClinical Pharmacology & Therapeutics, 2022
- Dexamethasone in Hospitalized Patients with Covid-19New England Journal of Medicine, 2021
- Trends in Oncology Clinical Trials Launched Before and During the COVID-19 PandemicJAMA Network Open, 2021
- Cuts in cancer research funding due to COVID-19The Lancet Oncology, 2020
- Clinical trial recovery from COVID-19 disruptionNature Reviews Drug Discovery, 2020